Car T-Cell Therapy

Researchers from Europe and the U.S. developed a hematologic toxicity score that can predict which patients are more likely to develop severe infections after chimeric antigen receptor T-cell therapy.

The FDA updated the prescribing information for axicabtagene ciloleucel to allow the use of prophylactic corticosteroids to manage the severity of certain treatment-related adverse events.

Clinicians who treat patients with chimeric antigen receptor T cells have become adept at identifying and treating acute neurotoxicity, a common adverse event associated with the therapy.

The FDA granted orphan drug designation to CTB001, an investigational chimeric antigen receptor T-cell therapy for treatment of certain gastric cancers.

B-cell acute lymphoblastic leukemia is the most common type of cancer among children.

The FDA granted orphan drug designation to CNCT19, a chimeric antigen receptor T-cell therapy for the treatment of relapsed or refractory acute lymphoblastic leukemia.

The FDA granted fast track and regenerative medicine advanced therapy designations to C-CAR039, a chimeric antigen receptor T-cell therapy in development for treatment of relapsed or refractory diffuse large B cell lymphoma.

An enhanced lymphodepletion regimen followed by chimeric antigen receptor T-cell therapy induced response among patients with relapsed or refractory B-cell malignancies, according to results presented at ASH Annual Meeting and Exposition.

The FDA granted regenerative medicine advanced therapy designation to CT041, a chimeric antigen receptor T-cell therapy for adults with relapsed or refractory gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.

The FDA lifted its clinical hold on a series of trials that use Allogene Therapeutics’ AlloCAR T chimeric antigen receptor T-cell therapies, according to a press release from the manufacturer.